213 related articles for article (PubMed ID: 23238591)
21. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
22. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
23. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.
Favaloro EJ; Kershaw G; Bukuya M; Hertzberg M; Koutts J
Haemophilia; 2001 Mar; 7(2):180-9. PubMed ID: 11260278
[TBL] [Abstract][Full Text] [Related]
24. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease.
White B; Lawler P; Riddell A; Nitu-Whalley IC; Hermans C; Lee CA; Brown SA
Br J Haematol; 2004 Jul; 126(1):100-4. PubMed ID: 15198739
[TBL] [Abstract][Full Text] [Related]
25. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
26. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
[TBL] [Abstract][Full Text] [Related]
27. Response to DDAVP in children with von Willebrand disease type 2.
Schneppenheim R; Budde U; Beutel K; Hassenpflug WA; Hauch H; Obser T; Oyen F; Schneppenheim S; Schrum J
Hamostaseologie; 2009 May; 29(2):143-8. PubMed ID: 19404524
[TBL] [Abstract][Full Text] [Related]
28. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
Mannucci PM
Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
Guddati AK; Rosovsky RP; Van Cott EM; Kuter DJ
Int J Lab Hematol; 2019 Jun; 41(3):325-330. PubMed ID: 30735311
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based recommendations on the treatment of von Willebrand disease in Italy.
Mannucci PM; Franchini M; Castaman G; Federici AB;
Blood Transfus; 2009 Apr; 7(2):117-26. PubMed ID: 19503633
[TBL] [Abstract][Full Text] [Related]
31. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Jacquemin M
Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
[TBL] [Abstract][Full Text] [Related]
32. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
[TBL] [Abstract][Full Text] [Related]
33. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
34. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
35. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
Arshad F; Stoof SC; Leebeek FW; Ruitenbeek K; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Kruip MJ; Lisman T
Liver Int; 2015 Jul; 35(7):1809-15. PubMed ID: 25522671
[TBL] [Abstract][Full Text] [Related]
36. Mild forms of von Willebrand disease: diagnosis and management.
Federici AB
Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
[TBL] [Abstract][Full Text] [Related]
37. von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy.
Favaloro EJ; Dean M; Grispo L; Exner T; Koutts J
Am J Hematol; 1994 Mar; 45(3):205-11. PubMed ID: 8296790
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
39. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
Cattaneo M; Simoni L; Gringeri A; Mannucci PM
Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of adult patients with von Willebrand disease in South Australia.
Rodgers SE; Lloyd JV; Mangos HM; Duncan EM; McRae SJ
Semin Thromb Hemost; 2011 Jul; 37(5):535-41. PubMed ID: 22102197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
